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Methods: Consecutive patients who underwent IVUS analysis after drug-eluting stent
implantation for de novo lesions were evaluated. Stent length was studied using automatic
pullback of an IVUS catheter (Boston Scientific Corp/SCIMED, MN) and was further
analyzed for change in length (IVUS - label)(mm), the absolute change in length [|IVUS
– label|](mm), and the absolute value of the relative change in length [|(IVUS-label)|/
label](%).
Results: A total of 183 stents were included: 38.3% sirolimus-eluting stents (SES);
27.9% zotarolimus-eluting stents (ZES); 20.2% Co-Ch everolimus-eluting stents (Cc-
EES); 7.1% Pl-Ch everolimus-eluting stents (Pc-EES) - the Element platform and 6.6%
paclitaxel-eluting stents (PES). The change in stent length (mm) and the relative change
in length (%) differed between groups: SES 0.3 1.2; ZES 1.0 1.3; Cc-EES 0.6 1.0;
Pc-EES 0.4  1.1; PES 0.1  1.4 (p0.008) and SES 1.7  6.0; ZES 5.7  6.7;
Cc-EES 3.5 5.8; Pc-EES 2.3 6.0; PES2.2 8.1 (p0.001), respectively. Relative
change in stent length was higher in the ZES group in comparison with SES and PES
groups, (p 0.001 for both). There were no statistical differences between the Pc-EES
(Element) and any other stent types. The rate of absolute relative change 5% in stent
length was lower in the SES group compared to the other groups: SES 34%; ZES 63%;
Cc-EES 54%; Pc-EES 46%; and PES 67% (p0.02). Significant (15%) absolute
relative change in length was rare (3.8%) and did not differ between groups (p0.54).
Long stents (20 mm, n62) had a higher absolute change in length when compared to
other stent groups (18 mm, n50 and 16 mm, n71): 1.3 1.0 vs. 1.0 0.6 vs. 1.0 
0.6, respectively (p0.02).
Conclusions: IVUS analysis revealed that significant change in stent length after
implantation was rare in all stent types. Stent axial integrity was influenced by stent
length; longer stents displayed a higher absolute change in length than did shorter stents.
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Background: We report for the first time a specific pattern of stent strut fracture in
everolimus-eluting stents (EES).
Methods: We retrospectively analyzed 439 consecutive stented lesions in 364 pts who
underwent intravascular ultrasound (IVUS) during EES follow-up from January 2011 to
February 2012.
Results: EES fractures were observed in 13 Xience V stents in 9 RCAs, 3 SVGs, and 1
LAD; 7 stent fractures (53.8%) were located near the ostium. Two layers of stent struts
were present within the length of a single stent in 11 of 13 stent fractures (84.6%),
indicating that fracture was followed by partial longitudinal stent overlap (Figure). By
IVUS, a 36.1 10.7 % smaller stent area was observed at the fractured site compared to
the adjacent non-fracture site. Focal in-stent restenosis (defined as an in-stent minimum
lumen area  4mm2 that was 10mm in length) was observed at 12 fractured sites
(92%); and cardiac events occurred in 12 pts (92%: 2 NSTEMI without angiographic
thrombus and 12 target lesion revascularizations).
Conclusions: Partial strut fracture with Xience V EES may result in overlap of the stent
edges proximal and distal to the site of fracture.
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Background: Case series have reported LSD associated with a range mechanisms,
platforms and clinical events. To further elucidate mechanisms we amalgamated pub-
lished reports with additional unpublished cases.
Methods: We reviewed reports and angiographic images from 38 cases from 6 centres.
An additional, 5 published cases and procedural details from 57 cases published from the
MAUDE database were included. 20 published cases were excluded due to insufficient
details.
Results: In 100 cases, LSD most commonly involved LAD and RCA interventions (38
and 34 cases) and LMS intervention (13 cases) and less commonly circumflex and graft
interventions (5 and 8 cases). LSD was associated with the Element type platform in 78
cases and associated with Driver/Endeavor, Biomatrix/Nobori, Resolute, Xience, and
Cypher platforms in 7,4,3,3,3 cases. The mechanism of LSD was identified in 78 cases.
LSD of the proximal stent was induced by the guide catheter in 25 cases (33%), re-entry
by a balloon catheter in 30cases, and other equipment in 3 cases. LSD of the distal stent
was induced by equipment withdrawl in 20 cases (25 %) involving IVUS catheters, filter
devices, previously inflated balloons, trapped wires. Several cases of distal LSD involved
secondary guide induced proximal LSD when the guide was sucked in. Treatment
involved further stenting or reballooning in 66 and 22 cases; with 12 cases that were not
re-expanded. Adverse procedural outcome involving emergency CABG was reported in
2 cases, and stent thrombosis in 5 cases.
Conclusions: The commonest mechanisms causing LSD were guide catheter contact and
postdilation balloon re-entry, with a further 25 cases caused by equipment withdrawl.
LSD occurred uncommonly with circumflex and graft interventions. It was successfully
treated by reballooning and/or restenting in most cases, but with a 7% incidence of
MACE. The commonest stent platform was the element type platform.
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Background: Peri-stent contrast staining (PSS) was defined as contrast staining outside
the stent contour extending to20% of the stent diameter. PSS could be related to in-stent
restenosis and very late stent thrombosis. Furthermore PSS is linked to in-stent restenosis
and stent fracture. We evaluated the prevalence and clinical implications of PSS after
evelolimus-eluting stent(EES) comparing those of sirolimus-eluting stent (SES).
Methods: From November 2002 to September 2011, we treated 5239 lesions with SES
and 2119 lesions with EES. We evaluated the PSS after SES and EES implantation at
follow-up coronary angiography. Data are shown in the table. The incidence of in-stent
restenosis and stent fracture among the lesions with diagnosis of PSS was compared
between SES and DES.
Results: Data are shown in the table.
Conclusions: The clinical implication of PSS after EES implantation was quite different
from those of SES implantation.
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